Reserpine treatment activates AMP activated protein kinase (AMPK)

Rackhyun Park, Kang Il Lee, Hyunju Kim, Minsu Jang, Thi Kim Quy Ha, Won Keun Oh, Junsoo Park

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Reserpine is a well-known medicine for the treatment of hypertension, however the role of reserpine in cell signaling is not fully understood. Here, we report that reserpine treatment induces the phosphorylation of AMP activated protein kinase (AMPK) at threonine 172 (T172) in PC12 cells. Phosphorylation of AMPK T172 is regulated by upstream signaling molecules, and the increase of phospho-T172 indicates that AMPK is activated. When we examined the FOXO3a dependent transcription by using the FHRE-Luc reporter assay, reserpine treatment repressed the FHRE-Luc reporter activity in a dose dependent manner. Finally, we showed that reserpine treatment induced the phosphorylation of AMPK as well as cell death in MCF-7 cells. These results suggest that AMPK is a potential cellular target of reserpine.

Original languageEnglish
Pages (from-to)157-161
Number of pages5
JournalNatural Product Sciences
Issue number3
Publication statusPublished - 2017

Bibliographical note

Funding Information:
This study was supported by a grant from the Leading Space Core Technology Development Program through the National Research Foundation funded by the Ministry of Science, ICT & Future Planning (2013M1A3A3A020424 33).

Publisher Copyright:
© 2017, Korean Society of Pharmacognosy. All rights reserved.

All Science Journal Classification (ASJC) codes

  • Drug Discovery
  • Organic Chemistry


Dive into the research topics of 'Reserpine treatment activates AMP activated protein kinase (AMPK)'. Together they form a unique fingerprint.

Cite this